Document Detail


Co-proccessed excipients with enhanced direct compression functionality for improved tableting performance.
MedLine Citation:
PMID:  22966909     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
It is necessary to have excipients with excellent functional properties to compensate for the poor mechanical properties and low aqueous solubility of the emerging active ingredients. Therefore, around 80% of the current drugs are not suitable for direct compression and more advanced excipients are required. Further, conventional grades of excipients cannot accommodate the technologically advanced high speed rotary tablet presses which require a powder with excellent flow, good compressibility, compactibility, particle size distribution and homogeneity of the ingredients. Co-processed excipients have been created to enhance the functional properties of the excipients and reduce their drawbacks. Co-processing is defined as the combination of two or more excipients by a physical process. Co-processed excipients are adequate for direct compression since they become multifunctional and thus, their dilution potential is high eliminating the need for many excipients in a formulation. In some cases, they are able to hold up to 50% of the drug in a formulation rendering compacts of good tableting properties. This study describes and discusses the functionality enhancement of commercial and investigational excipients through co-processing.
Authors:
John Rojas; Ira Buckner; Vijay Kumar
Related Documents :
21136639 - Neuroproteomics and its applications in research on nicotine and other drugs of abuse.
25067849 - The moral economy of violence in the us inner city.
24065599 - Different pharmaceutical products need similar terminology.
21246559 - Pegylated phosphotidylethanolamine inhibiting p-glycoprotein expression and enhancing r...
21219399 - Development of a core drug list towards improving prescribing education and reducing er...
21317459 - Evaluation of an actinomycin d/vx-680 aurora kinase inhibitor combination in p53-based ...
17048539 - Improved oral delivery of paclitaxel following administration in nanoemulsion formulati...
24341819 - A critical appraisal of microemulsions for drug delivery: part ii.
11689259 - Polymeric transdermal drug penetration enhancer. the enhancing effect of oligodimethyls...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drug development and industrial pharmacy     Volume:  38     ISSN:  1520-5762     ISO Abbreviation:  Drug Dev Ind Pharm     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802620     Medline TA:  Drug Dev Ind Pharm     Country:  England    
Other Details:
Languages:  eng     Pagination:  1159-70     Citation Subset:  IM    
Affiliation:
School of Pharmaceutical Chemistry, University of Antioquia , Medellin , Colombia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
Next Document:  Creating awareness and facilitating cervical and breast cancer screening uptake through the use of a...